| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/20/2005 | CN1211486C A DNA molecule encoding mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof |
| 07/20/2005 | CN1211374C Heterocyclic derivative, its preparation method and medicine compositioncontaining them |
| 07/20/2005 | CN1211368C Amorphous torasemide modification |
| 07/20/2005 | CN1211359C New phenalkyoxy-phenyl derivatives |
| 07/20/2005 | CN1211353C Unsaturated hydroximic acid derivatives as PARP inhibitors |
| 07/20/2005 | CN1211111C Antilipemic Chinese medicine |
| 07/20/2005 | CN1211109C Natural weight-reducing medicine |
| 07/20/2005 | CN1211107C Mixture for improving blood circulation |
| 07/20/2005 | CN1211097C Lotus-root cellulose particle preparation for treating obesity |
| 07/20/2005 | CN1211091C Polyallylamine polymers for treating hypercholesterolemia |
| 07/20/2005 | CN1211074C Solid-state liposome contaniing calcareous and its preparation method |
| 07/20/2005 | CN1211063C Compositions comprising organosiloxane resins for delivering oral care substances |
| 07/19/2005 | US6919460 Making 2-bromo-1-pyridin-3-yl-ethanol by reducing the ketone, protecting the alcohol, condensing with a p-(heterocycle)-phenoxyethylamine, then deprotecting to form 2-(2-(4-heterocycyl-phenoxy)-ethylamino)-1-pyridin-3-ylethanol |
| 07/19/2005 | US6919380 Carbocyclic esters such as 5-chloro-2-methanesulfonylindan-1--yl-4-chlorobenzoate, used as anorexigenic agents; dietetics |
| 07/19/2005 | US6919377 Cyclohexylamine derivative as subtype selective NMDA receptor antagonists |
| 07/19/2005 | US6919371 Antidiabetic agents; dietetics; gastrointestinal disorders |
| 07/19/2005 | US6919362 For use as hypoglycaemic and hypolipidaemic agents |
| 07/19/2005 | US6919355 Amide derivatives as NMDA receptor antagonists |
| 07/19/2005 | US6919354 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 07/19/2005 | US6919347 Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens |
| 07/19/2005 | US6919340 Kinase moderators; controlling gene expression; immunosuppressants; autoimmune disease; rheumatic disorders; skin disorders; antitumor agents; anticancer agents |
| 07/19/2005 | US6919339 ABCA-1 elevating compounds |
| 07/19/2005 | US6919332 Enzyme inhibitors such as 5-(2-Methoxy-ethyl)-5-(4-(1-pyridin -3-yl-1H-indazol-5-yloxy)-phenoxy)-pyrimidine-2,4,6-trione, used as antiinflammatory and anticarcinogenic agents |
| 07/19/2005 | US6919322 Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors |
| 07/19/2005 | US6919312 Polysaccharides |
| 07/19/2005 | US6919307 Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| 07/19/2005 | CA2071248C Composition containing dioxabicyclo-[3.3.0]octane derivative |
| 07/14/2005 | WO2005063790A1 Isolation of tigogenin pentaglycoside from chlorophytum nimonii |
| 07/14/2005 | WO2005063750A1 Bicyclic imidazole compounds, the production thereof and their use as medicaments |
| 07/14/2005 | WO2005063748A1 β-CARBOLINE DERIVED GUANIDINE ALKALOID, TIRUCHENDURAMINE |
| 07/14/2005 | WO2005063738A1 Novel 2-heteroaryl-substituted benzimidazole derivative |
| 07/14/2005 | WO2005063725A1 Phenylpropanoic acid derivatives |
| 07/14/2005 | WO2005063704A1 Azetidine ring compounds and drugs comprising the same |
| 07/14/2005 | WO2005063232A1 Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity |
| 07/14/2005 | WO2005063230A1 Use of conjugated linolenic acids for reducing body fat mass |
| 07/14/2005 | WO2005063228A1 Glucose tolerance-improving agent |
| 07/14/2005 | WO2005063227A1 Process for producing triterpene composition |
| 07/14/2005 | WO2005063169A2 Medical lipolysis of fat accumulations |
| 07/14/2005 | WO2005062824A2 Anti-hypercholesterolemic compounds |
| 07/14/2005 | WO2004046148A8 Novel xanthin derivatives, production and use thereof as medicaments |
| 07/14/2005 | WO2003059294A3 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/14/2005 | WO2003029424A3 Novel proteins and nucleic acids encoding same |
| 07/14/2005 | US20050155087 Method of screening compounds |
| 07/14/2005 | US20050154232 Nitrosation of the diphenylamine with an alkali metal nitrite in an acidic medium; the nitrosodiphenylamines increase the bioavailability of endothelial nitrogen monoxide; the diphenylamines are used as antioxidants and free radical scavengers; insulin resistance |
| 07/14/2005 | US20050154202 Substituted aryl amides |
| 07/14/2005 | US20050154165 Ph-sensitive polymer |
| 07/14/2005 | US20050154061 peroxisome-proliferator-activated receptor (PPAR)-delta agonist; 2-[4-[[[2-[(2,4-Dichlorophenyl)amino]-2-oxoethyl]cyclohexylamino]methyl]-2-methylphenoxy]-2-methylpropanoic acid; cardiovascular disorders, dyslipidaemias or restenosis; improves HDL/LDL cholesterol ratio; side effect reduction |
| 07/14/2005 | US20050154058 additives in food, cosmetic, pharmaceutical preparations; regioselective esterification of hydroxytyrosol (or oleuropein, oleuropein aglycones) by acylating agent (organic acid or ester) in presence of easily eliminated catalysts; more soluble in lipids; high chemical yields; high potency antioxidant |
| 07/14/2005 | US20050154039 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine |
| 07/14/2005 | US20050154038 bicyclo[2.2.2]-oct-1-yl-1,2,4-triazoles; type 2 diabetes, lipid disorders, obesity, atherosclerosis, metabolic syndrome, hyperglycemia, insulin resistance; increase insulin sensitivity in muscle, liver and adipose tissue by correction of the elevated plasma levels of glucose without causing hypoglycemia |
| 07/14/2005 | US20050154028 1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-imidazolidin-2-one; serotonin 5-ht2c receptor antagonist; antidepressant and anxiolytic agent |
| 07/14/2005 | US20050154025 6-[4-(fluoro- or trifluoromethyl)pyridyl-4-(p-fluorophenyl)-5-methylimidazol-2-yl] pyridones; cyclization of 1-phenyl-1-pyridyl-1,2-diaminopropanes with an acid, amidine, or nitrile compound; neuropeptide Y receptor antagonists; cardiovascular and central nervous system disorders, metabolic diseases |
| 07/14/2005 | US20050154019 Substituted cyclic amine metalloprotease inhibitors |
| 07/14/2005 | US20050154011 such as S)-3-Methylcarbamoyl-7-sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester, used in the treatment of protein tyrosine phosphatase (PTPase) mediated disorder such as diabetes |
| 07/14/2005 | US20050153996 Compounds that modulate ppar activity and methods for their preparation |
| 07/14/2005 | US20050153993 Treatment of statin side effects using uridine derivatives |
| 07/14/2005 | US20050153992 Glycogen synthase kinase-3 inhibitors; pyrrolo[3,2-d]pyrimidine: neurodegenerative diseases; antidiabetic, antiinflammatory, anticancer agents; 5-(2-aminoethyl)-6-(3-chloro(2-thienyl))-7-iodo-3-hydropyrrolo[3,2-d]pyrimidin-4-thione Trifluoroacetate; 4-halo intermediates |
| 07/14/2005 | US20050153987 Compounds |
| 07/14/2005 | US20050153980 Substituted indoles |
| 07/14/2005 | US20050153978 Medicaments |
| 07/14/2005 | US20050153973 (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes |
| 07/14/2005 | US20050153964 Novel compounds |
| 07/14/2005 | US20050153960 Substituted arylamine derivatives and methods of use |
| 07/14/2005 | US20050153952 Methods for inhibiting sterol absorption |
| 07/14/2005 | US20050153941 Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line |
| 07/14/2005 | US20050153906 Such as Hurler syndrome and Batten by administering an aminoglycosidesuch as gentamicin, G418, hygromycin B, paromomycin, tobramycin, lividomycin A, amikacin, sisomycin, or neomycin, optionally in combination with an enzyme effective for enzyme replacement therapy, a polyionic compound or gene therapy |
| 07/14/2005 | US20050153902 Inhibitors of integrin avb6 |
| 07/14/2005 | US20050153890 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 07/14/2005 | US20050153889 Modulation of pericyte proliferation |
| 07/14/2005 | US20050153888 oligopeptides capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM), used for treatment of normal, degenerated and damaged NCAM presenting cells |
| 07/14/2005 | US20050153870 Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome |
| 07/14/2005 | US20050153391 Polypeptides capable of binding to G protein coupled receptors as well as DNA encoding for such polypeptides; receptor binding assays; drug screening; obesity; prolactin production inhibitors |
| 07/14/2005 | US20050153315 Nucleotide sequences coding polypeptide comprising methylarginase activities for use in identifying modulator for prevention and treatment of ischemia-reperfusion injuries, cancer, hypotension, multi-organ failure, arthritis, skin, inflammatory, cardiac and/or migraine disorders |
| 07/14/2005 | US20050153018 pellets comprising compacted inner matrices containing viable microorganisms and moisture barrier coatings |
| 07/14/2005 | US20050152952 Phaseolamin compositions and methods for using the same |
| 07/14/2005 | US20050152897 Methods for inducing T cell tolerance to a tissue or organ graft |
| 07/14/2005 | US20050152871 treating the subject in need with one or more chemokines and/or a DNA damaging agent inducing said chemokine(s); |
| 07/14/2005 | US20050152848 covalently coupling insulin to one or more molecules of a non-naturally occurring hydrophilic polymer such as polyethylene glycol; antidiabetic agents |
| 07/14/2005 | DE10361067A1 Medikamentöse Lipolyse von Fettansammlungen Drug lipolysis of fat accumulation |
| 07/14/2005 | DE10359960A1 New glucopyranosyloxy-pyrazole derivatives are sodium dependent glucose cotransporter inhibitors used for treating and preventing metabolic disorders, particularly diabetes |
| 07/14/2005 | CA2552311A1 Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity |
| 07/14/2005 | CA2551611A1 Thiazole derivatives for treating or preventing parkinson's disease |
| 07/14/2005 | CA2551474A1 Medical lipolysis of fat accumulations |
| 07/14/2005 | CA2551227A1 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies |
| 07/14/2005 | CA2550649A1 3-(4-piperidine-1ylmethyl-phenyl)-propion acid-phenylamide-derivatives and related compounds used in the form of mch antagonists (melanine concentrating hormone) for treating eating disorders |
| 07/14/2005 | CA2545324A1 Aminoglycoside antibiotics for use as vap-1/ssao inhibitors |
| 07/13/2005 | EP1553098A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 07/13/2005 | EP1553097A1 Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore |
| 07/13/2005 | EP1553096A1 Pyrazole compounds |
| 07/13/2005 | EP1553094A1 Azulene derivatives and salts thereof |
| 07/13/2005 | EP1553091A1 Heteroaromatic pentacyclic compound and medicinal use thereof |
| 07/13/2005 | EP1553089A1 Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
| 07/13/2005 | EP1553084A1 Piperidine derivative, process for producing the same, and use |
| 07/13/2005 | EP1552842A1 Bicyclic pyrimidine derivatives |
| 07/13/2005 | EP1552832A1 Process for producing coated preparation |
| 07/13/2005 | EP1552830A1 Drug composition for prevention or inhibition of advance of diabetic complication |
| 07/13/2005 | EP1551972A2 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 07/13/2005 | EP1551872A2 G-protein coupled receptors |
| 07/13/2005 | EP1551860A1 Glucocorticoid receptor ligands for the treatment of metabolic disorders |
| 07/13/2005 | EP1551848A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |